ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Bone Marrow Plasma Cell Heterogeneity Drives Resistance of Proteasome Inhibitor Therapy

C. M. Castro-Rojas1, S. Tremblay2, J. Driscoll3, K. Roskin4, R. R. Alloway3, E. Woodle2, D. A. Hildeman1

1Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, 2Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, 3Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 4Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH

Meeting: 2020 American Transplant Congress

Abstract number: D-095

Keywords: B cells, HLA antibodies, Kidney transplantation, Sensitization

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session D: Kidney Immunosuppression: Desensitization

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • In Vivo Administration of Plerixafor in Humans Mobilizes Bone Marrow Resident Plasma Cells That Demonstrate Apoptosis in Both Bone Marrow and Peripheral Blood.
  • In Vivo Administration of Plerixafor and Bortezomib Results in Bone Marrow Plasma Cell Mobilization and Death While Inducing Biphasic Plasma Cell Apoptosis in Peripheral Blood

*Purpose: Patients sensitized to HLA antigens by prior transplantation, pregnancy or blood transfusion may have markedly prolonged waiting times for transplant. Moreover, once transplanted, the development of HLA antibodies (Abs) represent the primary cause of renal allograft loss. The proteasome inhibitors (PIs) carfilzomib and bortezomib target HLA Ab-producing bone marrow plasma cells (BMPCs) and reduce HLA Ab levels. However, the effects of PIs are suboptimal, often transient, and limited due to de novo or treatment-induced drug resistance that emerges through mechanisms that remain elusive. One potential explanation for plasma cell (PC) resistance is their residence within the BMPC niche, which current dogma suggests is orchestrated by the chemokine receptor CXCR4. Here, we evaluated the impact of bortezomib therapy after treatment with CXCR4/CXCL12 blocker (plerixafor) on PC populations in the blood and the bone marrow (BM).

*Methods: Peripheral blood and BM aspirates were collected before and after treatment with plerixafor +/- bortezomib from HLA-sensitized kidney transplant candidates. We performed a temporal assessment of anti-HLA-Abs by single antigen-bead assays, and PC mobilization to the blood and homeostasis within the BM were assessed by flow cytometry. After PBMC isolation, we characterized the CD138+CD38++IgG–CD27+PCs as newly formed plasma cells (NFPCs, CD19+) and long-lived plasma cells (LLPCs, CD19–). In addition, heterogeneity and transcriptomic analysis of individual CD138+ PCs from the BM were assessed before and after treatment by single cell RNA sequencing.

*Results: We observed that plerixafor preferentially mobilized CD19+ NFPCs into the peripheral blood. After bortezomib treatment, there was a substantial loss of NFPCs in the BM, while CD19–LLPCs were largely unaffected (Figure 1). We also observed transient loss of anti-HLA Abs as well as an upregulation of hypoxia-inducible factors (HIF)-signaling targets and apoptotic effectors in PCs following PI and plerixafor therapy (Figure 2).

*Conclusions: Our data show that plerixafor and bortezomib treatment has a preferential effect on NFPCs in the BM and that cells with hypoxic/HIF-1αsignature and low apoptotic potential are enriched in surviving cells.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Castro-Rojas CM, Tremblay S, Driscoll J, Roskin K, Alloway RR, Woodle E, Hildeman DA. Bone Marrow Plasma Cell Heterogeneity Drives Resistance of Proteasome Inhibitor Therapy [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/bone-marrow-plasma-cell-heterogeneity-drives-resistance-of-proteasome-inhibitor-therapy/. Accessed March 8, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.